For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not ...

You’ve likely heard the hype around Ozempic and Wegovy – weight loss drugs that have taken the world by storm. These ...

Glucagon-like peptide-1 receptor agonists are tied to a reduction in alcohol intake in patients being treated for obesity.

Understanding the goals of your patients can help alleviate some pushback from the start of an appointment.

This study assessed nutrient intake in adults using GLP-1 receptor agonists (GLP-1RAs) and found widespread deficiencies in ...

Patients taking a GLP-1 for diabetes have a lower risk for AF at 3 years than those on other medications, report ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being ...

First-generation GLP-1 drugs like liraglutide (Saxenda) and exenatide (Byetta) were associated with a 41% lower risk of ...

New research presented May 17 at the American Psychiatric Association's Annual Meeting shows that GLP-1 receptor agonists may ...

Data-driven clustering reveals distinct obesity phenotypes with unique clinical, behavioral, microbiome features, and differential GLP-1 responses.

While medications like Wegovy promise quick results, many people still prefer a drug-free path to shedding pounds. Science ...